Solian: Advanced Atypical Antipsychotic for Schizophrenia Management
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.25 | $97.49 (0%) | 🛒 Add to cart |
| 60 | $2.98 | $194.97 $178.89 (8%) | 🛒 Add to cart |
| 90 | $2.89 | $292.46 $260.30 (11%) | 🛒 Add to cart |
| 120 | $2.86 | $389.95 $342.71 (12%) | 🛒 Add to cart |
| 180 | $2.80 | $584.92 $504.52 (14%) | 🛒 Add to cart |
| 270 | $2.77
Best per pill | $877.39 $748.74 (15%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.98 | $89.45 (0%) | 🛒 Add to cart |
| 60 | $2.73 | $178.89 $163.82 (8%) | 🛒 Add to cart |
| 90 | $2.65 | $268.34 $238.19 (11%) | 🛒 Add to cart |
| 120 | $2.60 | $357.79 $312.56 (13%) | 🛒 Add to cart |
| 180 | $2.56 | $536.68 $460.30 (14%) | 🛒 Add to cart |
| 270 | $2.53
Best per pill | $805.03 $684.42 (15%) | 🛒 Add to cart |
Synonyms | |||
Solian (amisulpride) is a modern atypical antipsychotic medication designed for the effective treatment of schizophrenia and related psychotic disorders. It functions by modulating dopamine activity in the brain, specifically targeting both positive symptoms such as hallucinations and delusions, and negative symptoms including social withdrawal and apathy. With a well-established efficacy profile and a generally favorable side effect spectrum compared to older antipsychotics, Solian offers a balanced therapeutic option for long-term mental health management. Its selective receptor affinity contributes to a lower incidence of extrapyramidal symptoms, enhancing patient adherence and quality of life.
Features
- Active ingredient: Amisulpride
- Available in tablet form: 50 mg, 100 mg, 200 mg, 400 mg strengths
- Selective dopamine D2 and D3 receptor antagonist
- High bioavailability, not significantly affected by food
- Linear pharmacokinetics with dose proportionality
- Primarily renal excretion; dosage adjustment recommended in renal impairment
- Half-life of approximately 12 hours, supporting once- or twice-daily dosing
Benefits
- Effectively reduces both positive and negative symptoms of schizophrenia
- Lower risk of extrapyramidal side effects and weight gain compared to some other antipsychotics
- Improves social functioning and overall quality of life for patients
- Flexible dosing allows for personalized treatment regimens
- Generally well-tolerated, supporting long-term adherence
- May show efficacy in cases resistant to other antipsychotic treatments
Common use
Solian is primarily indicated for the treatment of schizophrenia in adults. It is used both in acute psychotic episodes and as maintenance therapy to prevent relapse. Clinical studies and practice have demonstrated its effectiveness across a broad spectrum of psychotic symptoms. It may also be used off-label under specialist supervision for other conditions such as dysthymia or borderline personality disorder, though such uses require careful risk-benefit evaluation. Treatment is usually initiated during a stable phase or under close monitoring during acute exacerbations.
Dosage and direction
Dosage must be individualized based on symptom profile, patient response, and tolerability. For positive symptoms, the usual dose ranges from 400 mg to 800 mg per day, administered orally in divided doses (twice daily). For predominant negative symptoms, lower doses of 50 mg to 300 mg per day may be effective. Dosage should be titrated gradually; treatment typically begins at the lower end of the range and is adjusted at intervals of several days to weeks. Tablets should be swallowed whole with water, with or without food. In patients with renal impairment, dosage reduction is necessary—consult prescribing information for specific guidance. Regular clinical assessment is advised to optimize dosing.
Precautions
Patients should be monitored for changes in mood, behavior, or emergence of suicidal thoughts, especially early in treatment or after dosage changes. Caution is advised in those with cardiovascular disease, seizure disorders, or Parkinson’s disease. Solian may impair alertness; patients should avoid driving or operating machinery until they know how the medication affects them. Regular monitoring of weight, blood glucose, lipid levels, and prolactin is recommended during long-term therapy. Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of mortality—use only if benefits clearly outweigh risks.
Contraindications
Solian is contraindicated in patients with known hypersensitivity to amisulpride or any excipients in the formulation. It should not be used in those with phaeochromocytoma. Concomitant use with levodopa is contraindicated. Solian is contraindicated in patients with prolactin-dependent tumours such as prolactinoma or breast cancer. It must not be administered to individuals with severe renal impairment (creatinine clearance <10 mL/min). Use is also contraindicated in combination with other drugs known to prolong QT interval, or in patients with known congenital long QT syndrome or significant cardiac arrhythmias.
Possible side effects
Common side effects (≥1/10) include insomnia, anxiety, and hyperkinesia. Other frequently reported reactions (≥1/100 to <1/10) include weight gain, drowsiness, hypotension, constipation, dry mouth, and elevated prolactin levels (which may lead to galactorrhea, amenorrhea, or gynecomastia). Uncommon side effects (≥1/1,000 to <1/100) include bradycardia, QT prolongation, extrapyramidal symptoms, and seizures. Rarely (≥1/10,000 to <1/1,000), neuroleptic malignant syndrome, tardive dyskinesia, or severe allergic reactions may occur. Most side effects are dose-dependent and may diminish over time; however, any persistent or severe reactions warrant medical attention.
Drug interaction
Solian may interact with other central nervous system depressants (e.g., alcohol, benzodiazepines), potentially enhancing sedative effects. Concomitant use with other antipsychotics may increase the risk of extrapyramidal symptoms or QT prolongation. Drugs that inhibit renal clearance (e.g., cimetidine) may increase amisulpride plasma levels. Caution is advised with medications that also affect dopamine systems, such as levodopa (contraindicated) or antidepressants. Solian may antagonize the effects of dopamine agonists. Use with drugs that prolong QT interval (e.g., certain antiarrhythmics, antibiotics) is not recommended. Always review the patient’s full medication list before prescribing.
Missed dose
If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the usual dosing schedule. Do not double the dose to make up for a missed one. Consistent dosing is important for maintaining stable plasma levels and therapeutic effect; patients should be advised to establish a routine to minimize missed doses. If multiple doses are missed, consult a healthcare provider for guidance on resuming therapy, as re-titration may be necessary.
Overdose
Symptoms of overdose may include severe drowsiness, sedation, hypotension, and extrapyramidal symptoms. In severe cases, QT prolongation, arrhythmias, coma, or respiratory depression may occur. There is no specific antidote for amisulpride overdose. Management is supportive and symptomatic: ensure airway patency, monitor cardiac and respiratory function, and administer activated charcoal if presentation is early. ECG monitoring is essential to detect QT prolongation. Hypotension should be managed with intravenous fluids and, if necessary, vasopressors. Avoid epinephrine in hypotensive patients due to risk of exacerbated hypotension. Extrapyramidal symptoms may be treated with anticholinergic agents. Contact a poison control center immediately.
Storage
Store Solian tablets at room temperature (15–30°C), in the original packaging to protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Dispose of any unused medication safely, in accordance with local regulations, to prevent accidental ingestion or environmental contamination. Do not flush medications down the toilet or drain unless instructed to do so.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Individual patient responses may vary; the prescribing physician should tailor therapy based on clinical evaluation and ongoing monitoring. The manufacturer and author are not liable for any adverse outcomes resulting from the use or misuse of this information.
Reviews
Clinical studies and post-marketing surveillance indicate that Solian is generally effective and well-tolerated in the management of schizophrenia. Many clinicians report good response in both acute and maintenance phases, with particular benefit for negative symptoms. Some patients note improved social engagement and reduced emotional blunting. Criticisms occasionally include prolactin-related side effects or the need for careful dose titration. Overall, it is regarded as a valuable option within the atypical antipsychotic class, especially when other agents have been ineffective or poorly tolerated. Long-term adherence appears favorable compared to some alternatives.